Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hao Qin Xiao Zhi Fang is a Traditional Chinese Medicine (TCM) herbal formula developed by Xiyuan Hospital of the China Academy of Chinese Medical Sciences. It is specifically designed for the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD), particularly targeting the "damp-heat accumulation" pattern according to TCM diagnostic principles. The formula aims to reduce hepatic fat accumulation and improve metabolic parameters such as lipid profiles and insulin sensitivity. It is currently being evaluated in a Phase 0 clinical trial to assess its efficacy and safety compared to lifestyle guidance alone, using controlled attenuation parameter (CAP) via FibroScan to quantify changes in liver steatosis over a 12-week period.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Hao Qin Xiao Zhi Fang.